SLC5A2 and diabetic kidney disease: In conclusion, we demonstrated that the SGLT2 inhibitor, dapagliflozin, ameliorates the characteristic changes of diabetic nephropathy and reduces albuminuria, as well as hyperglycemia and β-cell damage in db/db mice.